Ticker

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and offer dividend yields even higher than oil and gas stocks, as well as the "Magnificent 7." By opening this article, you will find out my "top 4 Big Pharma players."

Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.

JPMorgan Chase and Co. grew its holdings in Takeda Pharmaceutical Co. (NYSE: TAK) by 37.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 247,529 shares of the company's stock after acquiring an additional 67,770 shares during the quarter. JPMorgan Chase and Co.'s

Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy Transcript